
Opinion|Videos|July 31, 2024
Treatment Paradigms for Clinical Progression of CLL/SLL Beyond Initial Therapies
Author(s)Mazyar Shadman, MD, MPH
An expert on CLL/SLL provides clinical insights on approaching the treatment of patients who progress beyond initial therapy.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- How do you approach treatment for patients that progress beyond initial therapy in CLL/SLL?
- What factors influence the choice of retreatment options after prior BTK inhibitor therapy?
- What factors influence the choice of retreatment options after prior BTK inhibitor therapy?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
5



















